Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
American Journal of Cardiovascular Drugs

Open Access 03-04-2024 | Hypotension | Review Article

Advancing Guideline-Directed Medical Therapy in Heart Failure: Overcoming Challenges and Maximizing Benefits

Authors: Zixi Zhang, Cancan Wang, Tao Tu, Qiuzhen Lin, Jiabao Zhou, Yunying Huang, Keke Wu, Zeying Zhang, Wanyun Zuo, Na Liu, Yichao Xiao, Qiming Liu

Published in: American Journal of Cardiovascular Drugs

Login to get access

Abstract

The delayed titration of guideline-directed drug therapy (GDMT) is a complex event influenced by multiple factors that often result in poor prognosis for patients with heart failure (HF). Individualized adjustments in GDMT titration may be necessary based on patient characteristics, and every clinician is responsible for promptly initiating GDMT and titrating it appropriately within the patient’s tolerance range. This review examines the current challenges in GDMT implementation and scrutinizes titration considerations within distinct subsets of HF patients, with the overarching goal of enhancing the adoption and effectiveness of GDMT. The authors also underscore the significance of establishing a novel management strategy that integrates cardiologists, nurse practitioners, pharmacists, and patients as a unified team that can contribute to the improved promotion and implementation of GDMT.
Literature
1.
Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272–87.PubMedCrossRef
2.
3.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: executive summary: A report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022;145(18):e876–94.PubMed
4.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.PubMedCrossRef
5.
G. Savarese, T. Kishi, O. Vardeny, S. Adamsson Eryd, J. Bodegård, et al. Heart failure drug treatment—inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF). JACC Heart Fail. 11(1) (2023).
6.
Straw S, Cole CA, McGinlay M, Drozd M, Slater TA, et al. Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction. Clin Res Cardiol. 2023;112(1):111–22.PubMedCrossRef
7.
Spertus JA, Birmingham MC, Nassif M, Damaraju CV, Abbate A, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med. 2022;28(4):809–13.PubMedPubMedCentralCrossRef
8.
Riccioni G. Ivabradine: from molecular basis to clinical effectiveness. Adv Ther. 2010;27(3):160–7.PubMedCrossRef
9.
Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–85.PubMedCrossRef
10.
Abdin A, Anker SD, Butler J, Coats AJS, Kindermann I, et al. ‘Time is prognosis’ in heart failure: time-to-treatment initiation as a modifiable risk factor. ESC Heart Fail. 2021;8(6):4444–53.PubMedPubMedCentralCrossRef
11.
Abdin A, Bauersachs J, Soltani S, Eden M, Frey N, Böhm M. A practical approach to the guideline-directed pharmacological treatment of heart failure with reduced ejection fraction. ESC Heart Fail. 2023;10(1):24–31.PubMedCrossRef
12.
Seferović PM, Polovina M, Adlbrecht C, Bělohlávek J, Chioncel O, et al. Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. Eur J Heart Fail. 2021;23(12):1999–2007.PubMedCrossRef
13.
Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938–52.PubMedCrossRef
14.
Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72(4):351–66.PubMedCrossRef
15.
Maggioni AP, Anker SD, Dahlström U, Filippatos G, Ponikowski P, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15(10):1173–84.PubMedCrossRef
16.
Savarese G, Bodegard J, Norhammar A, Sartipy P, Thuresson M, et al. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). Eur J Heart Fail. 2021;23(9):1499–511.PubMedCrossRef
17.
Samsky MD, Lin L, Greene SJ, Lippmann SJ, Peterson PN, et al. Patient perceptions and familiarity with medical therapy for heart failure. JAMA Cardiol. 2020;5(3):292–9.PubMedCrossRef
18.
Trinkley KE, Kahn MG, Allen LA, Haugen H, Kroehl ME, et al. Patient treatment preferences for heart failure medications: a mixed methods study. Patient Prefer Adherence. 2020;14:2225–30.PubMedPubMedCentralCrossRef
19.
Khan MS, Segar MW, Usman MS, Singh S, Greene SJ, et al. Frailty, guideline-directed medical therapy, and outcomes in HFrEF: from the GUIDE-IT Trial. JACC Heart Fail. 2022;10(4):266–75.PubMedPubMedCentralCrossRef
20.
Rossignol P, Lainscak M, Crespo-Leiro MG, Laroche C, Piepoli MF, et al. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2020;22(8):1378–89.PubMedCrossRef
21.
Komajda M, Schöpe J, Wagenpfeil S, Tavazzi L, Böhm M, et al. Physicians’ guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2019;21(7):921–9.PubMedCrossRef
22.
Tsutsui H. Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines. Pharmacol Ther. 2022;238: 108185.PubMedCrossRef
23.
24.
Yamamoto K, Rakugi H. Angiotensin receptor-neprilysin inhibitors: comprehensive review and implications in hypertension treatment. Hypertens Res. 2021;44(10):1239–50.PubMedCrossRef
25.
Chatur S, Claggett BL, McCausland FR, Rouleau J, Zile MR, et al. Variation in renal function following transition to sacubitril/valsartan in patients with heart failure. J Am Coll Cardiol. 2023;81(15):1443–55.PubMedCrossRef
26.
Pereira Gray DJ, Sidaway-Lee K, White E, Thorne A, Evans PH. Continuity of care with doctors-a matter of life and death? A systematic review of continuity of care and mortality. BMJ Open. 2018;8(6): e021161.PubMedPubMedCentralCrossRef
27.
Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, et al. The Seattle Heart Failure model: prediction of survival in heart failure. Circulation. 2006;113(11):1424–33.PubMedCrossRef
28.
Canesin MF, Giorgi D, Oliveira MTd, Wajngarten M, Mansur AJ, et al. Ambulatory blood pressure monitoring of patients with heart failure. A new prognosis marker. Arq Bras Cardiol. 2002;78(1):83–9.PubMedCrossRef
29.
Lee TT, Chen J, Cohen DJ, Tsao L. The association between blood pressure and mortality in patients with heart failure. Am Heart J. 2006;151(1):76–83.PubMedCrossRef
30.
Rouleau JL, Roecker EB, Tendera M, Mohacsi P, Krum H, et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol. 2004;43(8):1423–9.PubMedCrossRef
31.
Metra M, Torp-Pedersen C, Swedberg K, Cleland JGF, Di Lenarda A, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J. 2005;26(21):2259–68.PubMedCrossRef
32.
Miller WL, Skouri HN. Chronic systolic heart failure, guideline-directed medical therapy, and systemic hypotension—less pressure but maybe more risk (does this clinical scenario need more discussion?). J Card Fail. 2009;15(2):101–7.PubMedCrossRef
33.
Izumi K, Kohno T, Goda A, Takeuchi S, Shiraishi Y, et al. Low blood pressure and guideline-directed medical therapy in patients with heart failure with reduced ejection fraction. Int J Cardiol. 2023;370:255–62.PubMedCrossRef
34.
Campbell DJ. Long-term neprilysin inhibition—implications for ARNIs. Nat Rev Cardiol. 2017;14(3):171–86.PubMedCrossRef
35.
Rosano GMC, Moura B, Metra M, Böhm M, Bauersachs J, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021;23(6):872–81.PubMedCrossRef
36.
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24.PubMedCrossRef
37.
38.
Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol. 2006;13(9):930–6.PubMedCrossRef
39.
Juraschek SP, Hu J-R, Cluett JL, Ishak AM, Mita C, et al. Orthostatic hypotension, hypertension treatment, and cardiovascular disease: an individual participant meta-analysis. JAMA. 2023;330(15):1459–71.PubMedCrossRef
40.
Giamouzis G, Kalogeropoulos AP, Butler J, Karayannis G, Georgiopoulou VV, et al. Epidemiology and importance of renal dysfunction in heart failure patients. Curr Heart Fail Rep. 2013;10(4):411–20.PubMedCrossRef
41.
Jingi AM, Nkoke C, Noubiap JJ, Teuwafeu D, Mambap AT, et al. Prevalence, correlates and in-hospital outcomes of kidney dysfunction in hospitalized patients with heart failure in Buea-Cameroon. BMC Nephrol. 2022;23(1):8.PubMedPubMedCentralCrossRef
42.
Denic A, Mathew J, Lerman LO, Lieske JC, Larson JJ, et al. Single-nephron glomerular filtration rate in healthy adults. N Engl J Med. 2017;376(24):2349–57.PubMedPubMedCentralCrossRef
43.
Harjola V-P, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca H-P, et al. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017;19(7):821–36.PubMedCrossRef
44.
Malhotra R, Craven T, Ambrosius WT, Killeen AA, Haley WE, et al. Effects of intensive blood pressure lowering on kidney tubule injury in CKD: a longitudinal subgroup analysis in SPRINT. Am J Kidney Dis. 2019;73(1):21–30.PubMedCrossRef
45.
Zhou S-H, Huang Q, Zhou Y, Cai X-X, Cui Y, et al. Captopril related kidney damage: renal afferent arteriolar responses to angiotensin II and inflammatory signaling. Sheng Li Xue Bao. 2022;74(1):125–33.PubMed
46.
McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation. 2004;109(8):1004–9.PubMedCrossRef
47.
Damman K, Gori M, Claggett B, Jhund PS, Senni M, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail. 2018;6(6):489–98.PubMedCrossRef
48.
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–20.PubMedCrossRef
49.
Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010;6(5):261–73.PubMedCrossRef
50.
Rossignol P, Dobre D, McMurray JJV, Swedberg K, Krum H, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014;7(1):51–8.PubMedCrossRef
51.
Rossignol P, Cleland JGF, Bhandari S, Tala S, Gustafsson F, et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation. 2012;125(2):271–9.PubMedCrossRef
52.
Mullens W, Martens P, Testani JM, Tang WHW, et al. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022;24(4):603–19.PubMedCrossRef
53.
Pandey AK, Dhingra NK, Hibino M, Gupta V, Verma S. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis. ESC Heart Fail. 2022;9(2):942–6.PubMedPubMedCentralCrossRef
54.
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.PubMedCrossRef
55.
Zannad F, Ferreira JP, Pocock SJ, Zeller C, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-reduced. Circulation. 2021;143(4):310–21.PubMedCrossRef
56.
Badve SV, Roberts MA, Hawley CM, Cass A, Garg AX, et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58(11):1152–61.PubMedCrossRef
57.
Ghali JK, Wikstrand J, Van Veldhuisen DJ, Fagerberg B, Goldstein S, et al. The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). J Card Fail. 2009;15(4):310–8.PubMedCrossRef
58.
Beldhuis IE, Lam CSP, Testani JM, Voors AA, Van Spall HGC, et al. Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. Circulation. 2022;145(9):693–712.PubMedPubMedCentralCrossRef
59.
Dzau VJ. Renal effects of angiotensin-converting enzyme inhibition in cardiac failure. Am J Kidney Dis. 1987;10(1 Suppl 1):74–80.PubMed
60.
Packer M, Lee WH, Medina N, Yushak M, Kessler PD. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med. 1987;106(3):346–54.PubMedCrossRef
61.
Gan L, Lyu X, Yang X, Zhao Z, Tang Y, et al. Application of angiotensin receptor-neprilysin inhibitor in chronic kidney disease patients: chinese expert consensus. Front Med (Lausanne). 2022;9: 877237.PubMedPubMedCentralCrossRef
62.
Henrysson J, Thunström E, Chen X, Fu M, Basic C. Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure. ESC Heart Fail. 2023;10(1):66–79.PubMedCrossRef
63.
Eschalier R, McMurray JJV, Swedberg K, van Veldhuisen DJ, Krum H, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol. 2013;62(17):1585–93.PubMedCrossRef
64.
Jering KS, Zannad F, Claggett B, Mc Causland FR, Ferreira JP, et al. Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF. JACC Heart Fail. 2021;9(1):13–24.PubMedCrossRef
65.
Desai AS, Vardeny O, Claggett B, McMurray JJV, Packer M, et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017;2(1):79–85.PubMedCrossRef
66.
Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, et al. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced. J Am Coll Cardiol. 2021;77(11):1397–407.PubMedCrossRef
67.
Harrington J, Fonarow GC, Khan MS, Hernandez A, Anker S, et al. Medication-attributable adverse events in heart failure trials. JACC Heart Fail. 2023;11(4):425–36.PubMedPubMedCentralCrossRef
68.
Cutshall BT, Duhart BT, Saikumar J, Samarin M, Hutchison L, et al. Assessing guideline-directed medication therapy for heart failure in end-stage renal disease. Am J Med Sci. 2018;355(3):247–51.PubMedCrossRef
69.
Butzner M, Riello RJ, Sarocco P, Desai N. Adverse drug effects across patients with heart failure: a systematic review. Am J Manag Care. 2022;28(3):e113–20.PubMedCrossRef
70.
Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015;372(3):222–31.PubMedCrossRef
71.
Oshima A, Imamura T, Narang N, Kinugawa K. Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate. Clin Cardiol. 2021;44(9):1272–5.PubMedPubMedCentralCrossRef
72.
Imamura T, Oshima A, Narang N, Kinugawa K. Clinical implications of sodium zirconium cyclosilicate therapy in patients with systolic heart failure and hyperkalemia. J Clin Med. 2021;10(23).
73.
Carlisle MA, Fudim M, DeVore AD, Piccini JP. Heart failure and atrial fibrillation, like fire and fury. JACC Heart Fail. 2019;7(6):447–56.PubMedCrossRef
74.
75.
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498.PubMedCrossRef
76.
Moysidis DV, Kartas A, Samaras A, Papazoglou AS, Patsiou V, et al. Prescription rates and prognostic implications of optimally targeted guideline-directed medical treatment in heart failure and atrial fibrillation: insights from the MISOAC-AF Trial. J Cardiovasc Pharmacol. 2023;81(3):203–11.PubMedCrossRef
77.
Loring Z, Shrader P, Allen LA, Blanco R, Chan PS, et al. Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. Am Heart J. 2020;219:21–30.PubMedCrossRef
78.
Ahn M-S, Yoo BS, Yoon J, Lee S-H, Kim JY, et al. Guideline-directed therapy at discharge in patients with heart failure and atrial fibrillation. Heart. 2020;106(4):292–8.PubMedCrossRef
79.
Kelly JP, DeVore AD, Wu J, Hammill BG, Sharma A, et al. Rhythm control versus rate control in patients with atrial fibrillation and heart failure with preserved ejection fraction: insights from get with the guidelines-heart failure. J Am Heart Assoc. 2019;8(24): e011560.PubMedPubMedCentralCrossRef
80.
Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016;133(17):1637–44.PubMedCrossRef
81.
Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321(13):1261–74.PubMedPubMedCentralCrossRef
82.
Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417–27.PubMedCrossRef
83.
Giunta H. Treatment incentives and the nature of the doctor-patient relationship. Am J Bioeth. 2016;16(10):77–8.PubMedCrossRef
84.
Fitzgerald AA, Powers JD, Ho PM, Maddox TM, Peterson PN, et al. Impact of medication nonadherence on hospitalizations and mortality in heart failure. J Card Fail. 2011;17(8):664–9.PubMedCrossRef
85.
Annema C, Luttik M-L, Jaarsma T. Reasons for readmission in heart failure: Perspectives of patients, caregivers, cardiologists, and heart failure nurses. Heart Lung. 2009;38(5):427–34.PubMedCrossRef
86.
van der Wal MHL, Jaarsma T, Moser DK, Veeger NJGM, van Gilst WH, et al. Compliance in heart failure patients: the importance of knowledge and beliefs. Eur Heart J. 2006;27(4):434–40.PubMedCrossRef
87.
Ruppar TM, Cooper PS, Mehr DR, Delgado JM, Dunbar-Jacob JM. Medication adherence interventions improve heart failure mortality and readmission rates: systematic review and meta-analysis of controlled trials. J Am Heart Assoc. 2016;5(6):e002606. https://​doi.​org/​10.​1161/​JAHA.​115.​002606.
88.
89.
90.
Comín-Colet J, Enjuanes C, Verdú-Rotellar JM, Linas A, Ruiz-Rodriguez P, et al. Impact on clinical events and healthcare costs of adding telemedicine to multidisciplinary disease management programmes for heart failure: results of a randomized controlled trial. J Telemed Telecare. 2016;22(5):282–95.PubMedCrossRef
91.
Hernandez LS. Role of telemedicine in improving guideline-directed medical treatment for patients with heart failure during a pandemic. Crit Care Nurs Clin N Am. 2022;34(2):151–6.CrossRef
92.
Clark KAA, Defilippis EM, Morris AA. Breaking the bank: the financial burden of living with heart failure. J Card Fail. 2022;28(9):1434–6.PubMedCrossRef
93.
Sen S. Heart failure with reduced ejection fraction: clinical and economic burden and insights into current and emerging treatments. Am J Manag Care. 2023;29(10 Suppl):S180–6.PubMed
94.
Ali H-JR, Valero-Elizondo J, Wang SY, Cainzos-Achirica M, Bhimaraj A, et al. Subjective financial hardship due to medical bills among patients with heart failure in the United States: the 2014–2018 Medical Expenditure Panel Survey. J Card Fail. 2022;28(9):1424–33.PubMedCrossRef
95.
Pierce JB, Ikeaba U, Peters AE, DeVore AD, Chiswell K, et al. Quality of care and outcomes among patients hospitalized for heart failure in rural vs urban us hospitals: the get with the guidelines-heart failure registry. JAMA Cardiol. 2023;8(4):376–85.PubMedPubMedCentralCrossRef
96.
Peterson PN, Rumsfeld JS, Liang L, Hernandez AF, Peterson ED, et al. Treatment and risk in heart failure: gaps in evidence or quality? Circ Cardiovasc Qual Outcomes. 2010;3(3):309–15.PubMedCrossRef
97.
Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, et al. Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73(19):2365–83.PubMedPubMedCentralCrossRef
98.
Driscoll A, Currey J, Tonkin A, Krum H. Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction. Cochrane Database Syst Rev. 2015;12:CD009889.
99.
King-Dailey K, Frazier S, Bressler S, King-Wilson J. The role of nurse practitioners in the management of heart failure patients and programs. Curr Cardiol Rep. 2022;24(12):1945–56.PubMedPubMedCentralCrossRef
100.
McLachlan A, Aldridge C, Morgan M, Lund M, Gabriel R, Malez V. An NP-led pilot telehealth programme to facilitate guideline-directed medical therapy for heart failure with reduced ejection fraction during the COVID-19 pandemic. N Z Med J. 2021;134(1538):77–88.PubMed
101.
Zheng J, Mednick T, Heidenreich PA, Sandhu AT. Pharmacist- and nurse-led medical optimization in heart failure: a systematic review and meta-analysis. J Card Fail. 2023;29:1000–13.PubMedCrossRef
102.
103.
Banayan J, Rana S, Mueller A, Tung A, Ramadan H, et al. Cardiogenic shock in pregnancy: analysis from the National Inpatient Sample. Hypertens Pregnancy. 2017;36(2):117–23.PubMedCrossRef
104.
Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(2):207–21.PubMedCrossRef
105.
McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, et al. Clinical outcomes for peripartum cardiomyopathy in north america: results of the IPAC study (investigations of pregnancy-associated cardiomyopathy). J Am Coll Cardiol. 2015;66(8):905–14.PubMedPubMedCentralCrossRef
106.
Arrigo M, Biegus J, Asakage A, Mebazaa A, Davison B, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure in elderly patients: a sub-analysis of the STRONG-HF randomized clinical trial. Eur J Heart Fail. 2023;25(7):1145–55.PubMedCrossRef
107.
Cheng JWM, Nayar M. A review of heart failure management in the elderly population. Am J Geriatr Pharmacother. 2009;7(5):233–49.PubMedCrossRef
108.
Kitzman DW, Upadhya B. Age-related divergence of risk-benefit relationship of spironolactone treatment for heart failure with preserved ejection fraction. JACC Heart Fail. 2019;7(12):1029–31.PubMedPubMedCentralCrossRef
109.
110.
Pop-Busui R, Januzzi JL, Bruemmer D, Butalia S, Green JB, et al. Heart failure: an underappreciated complication of diabetes A consensus report of the American Diabetes Association. Diabetes Care. 2022;45(7):1670–90.PubMedPubMedCentralCrossRef
111.
Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI With ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail. 2016;9(1):e002560. https://​doi.​org/​10.​1161/​CIRCHEARTFAILURE​.​115.​002560.
112.
Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial. Circulation. 2021;143(4):326–36.PubMedCrossRef
113.
Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial. Circulation. 2021;144(16):1284–94.PubMedPubMedCentralCrossRef
114.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069–84.PubMedCrossRef
115.
Marso SP, Baeres FMM, Bain SC, Goldman B, Husain M, et al. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure. J Am Coll Cardiol. 2020;75(10):1128–41.PubMedCrossRef
Metadata
Title
Advancing Guideline-Directed Medical Therapy in Heart Failure: Overcoming Challenges and Maximizing Benefits
Authors
Zixi Zhang
Cancan Wang
Tao Tu
Qiuzhen Lin
Jiabao Zhou
Yunying Huang
Keke Wu
Zeying Zhang
Wanyun Zuo
Na Liu
Yichao Xiao
Qiming Liu
Publication date
03-04-2024

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits